Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.


Journal Article

To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination.Thirty-nine evaluable patients with advanced solid tumors were treated with gemcitabine (Gem) and irinotecan (Iri) on days 1, 8 and 15 of a 28-day cycle. Dose levels included Gem/Iri 700/50, 900/50, 900/75, 500/50 mg/m(2) respectively. Dose-limiting toxicity (DLT) was assessed during cycle one; toxicity evaluation was closely monitored throughout the course of treatment. Treatment continued until disease progression or unacceptable toxicity.DLTs primarily consisted of grade > or = 3 thrombocytopenia lasting > or = 4 days often accompanied by grade > or = 3 neutropenia. Other grade > or = 3 toxicities included vomiting, diarrhea, fatigue and elevated alkaline phosphatase. Three patients had a partial response. Stable disease as best response was seen in 16 patients, ranging from 2-18 months.The MTD/RPTD is gemcitabine 500 mg/m(2) plus irinotecan 50 mg/m(2) on days 1, 8 and 15 of a 28-day cycle. Given the toxicity profile and negative results of phase III studies, no further testing of this treatment combination is recommended.

Full Text

Duke Authors

Cited Authors

  • Dugan, E; Truax, R; Meadows, KL; Blobe, GC; Morse, MA; Fernando, NH; Gockerman, JP; Petros, WP; Hurwitz, HI

Published Date

  • December 2009

Published In

Volume / Issue

  • 29 / 12

Start / End Page

  • 5149 - 5153

PubMed ID

  • 20044630

Pubmed Central ID

  • 20044630

Electronic International Standard Serial Number (EISSN)

  • 1791-7530

International Standard Serial Number (ISSN)

  • 0250-7005


  • eng